Literature DB >> 17316407

Drug transporters in the epileptic brain.

Wolfgang Löscher1.   

Abstract

Current estimates indicate that up to one-third of all individuals with epilepsy are refractory to antiepileptic drug (AED) therapy. Moreover, most of these people are resistant to multiple drugs with a wide range of mechanistic actions. These observations suggest that the development of multidrug resistance involves nonspecific, global changes in the brain. The multidrug transporter hypothesis of pharmacoresistant epilepsy proposes that regional-specific overexpression of drug efflux transporters in the blood-brain barrier limits the brain penetration of AEDs. Consequently, drug concentrations are too low to induce antiepileptic effects at target brain sites. Cumulative clinical and experimental data support this hypothesis and offer novel therapeutic approaches for the treatment of drug-resistant epilepsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316407     DOI: 10.1111/j.1528-1167.2007.00993.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  20 in total

1.  Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.

Authors:  Bo-Ting Zhou; Qiu-Hong Zhou; Ji-Ye Yin; Guo-Liang Li; Jian Qu; Xiao-Jing Xu; Ding Liu; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2012-05-17       Impact factor: 5.243

Review 2.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

3.  Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier.

Authors:  David B Banks; Gary Ny Chan; Rebecca A Evans; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-27       Impact factor: 6.200

4.  Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.

Authors:  Detlev Boison; Susan A Masino; Jonathan D Geiger
Journal:  Expert Opin Drug Discov       Date:  2011-07       Impact factor: 6.098

5.  Altered expression of brain monocarboxylate transporter 1 in models of temporal lobe epilepsy.

Authors:  Fredrik Lauritzen; Edgar L Perez; Eric R Melillo; Jung-Min Roh; Hitten P Zaveri; Tih-Shih W Lee; Yue Wang; Linda H Bergersen; Tore Eid
Journal:  Neurobiol Dis       Date:  2011-08-10       Impact factor: 5.996

6.  Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus.

Authors:  Fredrik Lauritzen; Nihal C de Lanerolle; Tih-Shih W Lee; Dennis D Spencer; Jung H Kim; Linda H Bergersen; Tore Eid
Journal:  Neurobiol Dis       Date:  2010-11-25       Impact factor: 5.996

Review 7.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 8.  Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications.

Authors:  P Kannan; C John; S S Zoghbi; C Halldin; M M Gottesman; R B Innis; M D Hall
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

9.  Multidrug resistance proteins expression in glioma patients with epilepsy.

Authors:  Chiara Calatozzolo; Bianca Pollo; Andrea Botturi; Loredana Dinapoli; Mariantonia Carosi; Andrea Salmaggi; Marta Maschio
Journal:  J Neurooncol       Date:  2012-07-26       Impact factor: 4.130

Review 10.  Contributions of astrocytes to epileptogenesis following status epilepticus: opportunities for preventive therapy?

Authors:  M B Gibbons; R M Smeal; D K Takahashi; J R Vargas; K S Wilcox
Journal:  Neurochem Int       Date:  2012-12-21       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.